Our results of overall reduced mGlu5 receptor expression in relevant regions of the brain in individuals with FXS replicate recent findings17 and advance ongoing efforts for a much-needed measure of mGluR5 target engagement for drugs and treatment of symptoms in clinical trials of FXS and related disorders36,37. The gene discussed is GRM5; the disease is fragile X syndrome.